HOME > Detail View

Detail View

Small molecules in oncology [electronic resource] / 2nd ed

Small molecules in oncology [electronic resource] / 2nd ed

Material type
E-Book(소장)
Personal Author
Martens, Uwe M.
Title Statement
Small molecules in oncology [electronic resource] / Uwe M. Martens (ed.).
판사항
2nd ed.
Publication, Distribution, etc
Berlin;   Heidelberg :   Springer Berlin Heidelberg :   Imprint: Springer,   2014.  
Physical Medium
1 online resource (xvi, 417 p.) : ill. (some col.).
Series Statement
Recent results in cancer research,0080-0015 ; 201
ISBN
9783642544903
요약
Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
General Note
Title from e-Book title page.  
Content Notes
Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
Bibliography, Etc. Note
Includes bibliographical references.
이용가능한 다른형태자료
Issued also as a book.  
Subject Added Entry-Topical Term
Cancer --Molecular aspects. Antineoplastic agents. Cancer --Treatment. Neoplasms --drug therapy. Antineoplastic Agents --therapeutic use. Azacitidine --therapeutic use. Protein Kinase Inhibitors --therapeutic use.
Short cut
URL
000 00000nam u2200205 a 4500
001 000046049850
005 20201015131542
006 m d
007 cr
008 201005s2014 gw a ob 000 0 eng d
020 ▼a 9783642544903
040 ▼a 211009 ▼c 211009 ▼d 211009
050 4 ▼a RC254-282
082 0 4 ▼a 616.994061 ▼2 22
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
245 0 0 ▼a Small molecules in oncology ▼h [electronic resource] / ▼c Uwe M. Martens (ed.).
250 ▼a 2nd ed.
260 ▼a Berlin; ▼a Heidelberg : ▼b Springer Berlin Heidelberg : ▼b Imprint: Springer, ▼c 2014.
300 ▼a 1 online resource (xvi, 417 p.) : ▼b ill. (some col.).
490 1 ▼a Recent results in cancer research, ▼x 0080-0015 ; ▼v 201
500 ▼a Title from e-Book title page.
504 ▼a Includes bibliographical references.
505 0 ▼a Imatinib Mesylate -- Erlotinib -- Axitinib (AG-013736) -- Lapatinib -- Sorafenib -- Sunitinib -- Dasatinib -- Nilotinib -- Bosutinib -- Decitabine -- Azacytidine/Azacitidine -- Bortezomib -- Temsirolimus -- Danusertib -- Vismodegib -- Everolimus -- Vemurafenib -- Vandetanib -- Trametinib -- Dabrafenib -- Ponatinib -- Regorafenib -- Cabozantinib -- Revlimid -- Ibrutinib -- Qizartinib -- Ruxolitinib -- Carfilzomib -- Afitinib.
520 ▼a Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Cancer ▼x Molecular aspects.
650 0 ▼a Antineoplastic agents.
650 0 ▼a Cancer ▼x Treatment.
650 1 2 ▼a Neoplasms ▼x drug therapy.
650 2 2 ▼a Antineoplastic Agents ▼x therapeutic use.
650 2 2 ▼a Azacitidine ▼x therapeutic use.
650 2 2 ▼a Protein Kinase Inhibitors ▼x therapeutic use.
700 1 ▼a Martens, Uwe M.
830 0 ▼a Recent results in cancer research ; ▼v 201.
856 4 0 ▼u https://oca.korea.ac.kr/link.n2s?url=http://dx.doi.org/10.1007/978-3-642-54490-3
945 ▼a KLPA
991 ▼a E-Book(소장)

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Main Library/e-Book Collection/ Call Number CR 616.994061 Accession No. E14034710 Availability Processing Due Date Make a Reservation Service M

New Arrivals Books in Related Fields